Nout, R.A., Smit, V.T., Putter, H., Jürgenliemk-Schulz, I.M., Jobsen, J.J., Lutgens, L.C., et al. (2010) Vaginal Brachytherapy versus Pelvic External Beam Radiotherapy for Patients with Endometrial Cancer of High-Intermediate Risk (PORTEC-2): An Open-Label, Non-Inferiority, Randomised Trial. Lancet, 375, 816-823. http://dx.doi.org/10.1016/S0140-6736(09)62163-2

has been cited by the following article:

• TITLE: Treatment Results of Adjuvant Brachytherapy as Monotherapy in Endometrial Cancer: A Retrospective Study from Faculty of Medicine, Chiang Mai University

  AUTHORS: Ekkasit Tharavichitkul, Sukon Prasitwattanaseree, Cholthicha Thipmate, Somvilai Chakrabandhu, Pitchayaponne Klunklin, Wimrak Onchan, Razvan M. Galalae, Imjai Chitapanarux

  KEYWORDS: Endometrial Cancer, Adjuvant, Brachytherapy, Monotherapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.1, December 31, 2014

  ABSTRACT: Purpose: To report the retrospective study of using intravaginal brachytherapy as adjuvant monotherapy for endometrial cancer. Materials and Methods: From 2001-2009, 47 patients who received completely surgical staging for endometrial carcinoma and were designed by multidisciplinary team were enrolled. All patients received intravaginal brachytherapy (IVBT) with the dose of 5.5 - 7 Gy in 2 - 6 fractions. The treatment results and late toxicities were evaluated and recorded. Results: At the median follow-up time of 44 months, the local control, disease-free survival, metastasis-free survival and overall survival rates were 100%, 97.9%, 97.9% and, 97.9%, respectively. Only age showed the statistical significance with the p-value of 0.046. Two patients (4.3%) developed late genitourinary toxicity. Conclusion: The using of adjuvant IVBT as monotherapy for endometrial carcinoma is feasible.